Trials / Completed
CompletedNCT04035226
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 254 (actual)
- Sponsor
- Janssen-Cilag Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | No intervention will be administered as a part of this study. |
Timeline
- Start date
- 2019-08-02
- Primary completion
- 2022-10-27
- Completion
- 2022-10-27
- First posted
- 2019-07-29
- Last updated
- 2025-03-30
Locations
75 sites across 10 countries: United States, Belgium, France, Germany, Italy, Netherlands, Poland, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04035226. Inclusion in this directory is not an endorsement.